Abstract
Cumulative scientific evidence gathered over the past ten years has confirmed the role of platelet GP IIb / IIIa inhibitors in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). Recently, mortality data available on more than 20,000 patients enrolled in randomized clinical trials suggest that GP IIb / IIIa blockade also improves short and long-term survival after PCI. Despite convincing arguments, GP IIb / IIIa inhibitors are still inconsistently administered in patients undergoing coronary intervention. The following review will discuss the scientific grounds and the principal controversies surrounding the use of these compounds in patients undergoing elective percutaneous coronary intervention.
Keywords: Coronary Intervention, IIIa inhibitors, GP IIb
Current Pharmaceutical Design
Title: GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention
Volume: 10 Issue: 4
Author(s): Dery J.P., Harrington R.A. and Tcheng J.E.
Affiliation:
Keywords: Coronary Intervention, IIIa inhibitors, GP IIb
Abstract: Cumulative scientific evidence gathered over the past ten years has confirmed the role of platelet GP IIb / IIIa inhibitors in reducing ischemic complications of patients undergoing percutaneous coronary intervention (PCI). Recently, mortality data available on more than 20,000 patients enrolled in randomized clinical trials suggest that GP IIb / IIIa blockade also improves short and long-term survival after PCI. Despite convincing arguments, GP IIb / IIIa inhibitors are still inconsistently administered in patients undergoing coronary intervention. The following review will discuss the scientific grounds and the principal controversies surrounding the use of these compounds in patients undergoing elective percutaneous coronary intervention.
Export Options
About this article
Cite this article as:
Dery J.P. , Harrington R.A. and Tcheng J.E. , GP IIb / IIIa Blockade in Elective Percutaneous Coronary Intervention, Current Pharmaceutical Design 2004; 10 (4) . https://dx.doi.org/10.2174/1381612043453306
DOI https://dx.doi.org/10.2174/1381612043453306 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Patent Selections:
Recent Patents on Cardiovascular Drug Discovery Cholesteryl Ester Transfer Protein: Pharmacological Inhibition for the Modulation of Plasma Cholesterol Levels and Promising Target for the Prevention of Atherosclerosis.
Current Topics in Medicinal Chemistry Let Them Eat Cake
Current Nutrition & Food Science Menopause and its Cardiometabolic Consequences: Current Perspectives
Current Vascular Pharmacology Preface [Hot topic: Angiogenesis Agents (Executive Editor: Cezary Marcinkiewicz)]
Current Pharmaceutical Design Risk Factors for Myocardial Infarction in Women and Men: A Review of the Current Literature
Current Pharmaceutical Design Fatty Acids and Effects on In Vitro and In Vivo Models of Liver Steatosis
Current Medicinal Chemistry Endothelial Dysfunction, Obesity and Insulin Resistance
Current Vascular Pharmacology Use of Alternative Antiplatelet Agents for Clopidogrel Hypersensitivity
Current Vascular Pharmacology Obesity- An Adverse Factor in Reproductive Age
Applied Clinical Research, Clinical Trials and Regulatory Affairs Selective Peroxisome Proliferator-Activated Receptor-γ Modulation to Reduce Cardiovascular Risk in Patients with Insulin Resistance
Recent Patents on Cardiovascular Drug Discovery Thrombolysis in Ischemic Stroke: Focus on New Treatment Strategies
Recent Patents on Cardiovascular Drug Discovery Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design Gene Therapy in Disorders of Lipoprotein Metabolism
Current Gene Therapy Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants
Current Pharmaceutical Design Augmentation Therapy with Alpha1-antitrypsin: Novel Perspectives
Cardiovascular & Hematological Disorders-Drug Targets The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Apolipoprotein(a) in the Carotid Artery Plaque: Evidence for Proteolytic and Pro-Inflammatory Modifications
Vascular Disease Prevention (Discontinued) Interstitial Lung Disease Associated with Collagen Vascular Disease
Clinical Anti-Inflammatory & Anti-Allergy Drugs (Discontinued) Current Pharmacological Approach to Restore Endothelial Dysfunction
Cardiovascular & Hematological Agents in Medicinal Chemistry